Linda Ashcroft

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Corinne Faivre‐Finn, M. Snee, Linda Ashcroft et al. · The Lancet Oncology · 2017 · 570 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent

D. Gareth Evans, Fiona Lalloo, Linda Ashcroft et al. · Cancer Epidemiology Biomarkers & Prevention · 2009 · 149 citations

Medicine, Genetics, Oncology +17

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials

Paul Wheatley‐Price, Fiona Blackhall, Siow Ming Lee et al. · Annals of Oncology · 2010 · 122 citations

Medicine, Oncology, Pathology +12

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma

Sarah Danson, Paul Lorigan, Ana Arance et al. · Journal of Clinical Oncology · 2003 · 109 citations

Medicine, Oncology, Pharmacology +16

ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

Richard Booton, Tim Ward, Linda Ashcroft et al. · Journal of Thoracic Oncology · 2007 · 104 citations · Full text

Medicine, Cancer Biology, Oncology +10